The incidence of post-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT) treated with direct oral anticoagulants (DOACs) remains a matter of debate. Hence, our endeavor to investigate a large cohort of patients with a first episode of proximal DVT treated with DOACs to ascertain the incidence and predisposing risk factors for PTS. All consecutive patients referred to the Thrombotic and Haemorrhagic Diseases Unit of Padova University Hospital (Italy) between January 2014 and January 2018 for a first episode of proximal DVT were considered for enrollment. Participants received DOACs for a minimum period of 3 months. PTS was assessed using the Villalta score up to 36 months after DVT diagnosis. Among 769 enrolled patients (M/F 353/416, age range 26–87 years), 152 (19.8%) developed PTS and 30 (3.9%) developed severe PTS. The adjusted hazard ratio was significant for obesity (1.64, 95% CI 1.28–2.39) and DVT site (femoral and/or iliac veins vs popliteal vein) (1.23, 95% CI 1.15–3.00). The incidence of PTS is not negligible in patients with proximal DVT despite the use of DOACs. We identified obesity and iliofemoral DVT as possible risk factors for PTS. Larger prospective studies are needed to confirm our findings and optimize therapeutic strategies.
KahnSR. The post-thrombotic syndrome. Hematol Am Soc Hematol Educ Program2016; 2016: 413–418.
2.
FarrellJJSutterCTavriS, et al.Incidence and interventions for post-thrombotic syndrome. Cardiovasc Diagn Ther2016; 6: 623–631.
3.
AgenoWPiantanidaEDentaliF, et al.Body mass index is associated with the development of the post-thrombotic syndrome. Thromb Haemostasis2003; 89: 305–309.
4.
TickLWKramerMHRosendaalFR, et al.Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemostasis2008; 6: 2075–2081.
5.
van DongenCJPrandoniPFrullaM, et al.Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemostasis2005; 3: 939–942.
6.
ChitsikeRSRodgerMAKovacsMJ, et al.Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. J Thromb Haemostasis2012; 10: 2039–2044.
7.
DronkersCEAMolGCMarazitiG, et al.Predicting post-thrombotic syndrome with ultrasonographic follow-up after deep vein thrombosis: a systematic review and meta-analysis. Thromb Haemostasis2018; 118: 1428–1438.
8.
KahnSRShbakloHLampingDL, et al.Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemostasis2008; 6: 1105–1112.
9.
MacDougallDAFeliuALBoccuzziSJ, , et al.Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm2006; 63: S5–S15.
10.
AshraniAAHeitJA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis2009; 28: 465–476.
11.
LiRYuanMChengJ, et al.Risk of post-thrombotic syndrome after deep vein thrombosis treated with rivaroxaban versus vitamin-K antagonists: a systematic review and meta-analysis. Thromb Res2020; 196: 340–348.
12.
KarathanosCNanaPSpanosK, et al.Efficacy of rivaroxaban in prevention of post-thrombotic syndrome: a systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord2021; 9(6): 1568–1576.e1.
13.
KearonCAklEAComerotaAJ, et al.Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest2012; 141: e419S–e496S.
14.
KahnSRComerotaAJCushmanM, et al.The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the american heart association. Circulation2014; 130: 1636–1661.
15.
KahnSRGalanaudJPVedanthamS, , et al.Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis2016; 41: 144–153.
16.
TranHAGibbsHMerrimanE, et al.New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust2019; 210: 227–235.
17.
VillaltaSBagatellaPPiccioliA, et al.Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Haemostasis1994; 24: 158a.
18.
CampelloESpieziaLSimionC, et al.Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc2020; 9: e018917.
19.
CheungYWMiddeldorpSPrinsMH, et al.Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemostasis2016; 116: 733–738.
20.
JerajLJezovnikMKPoredosP. Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome. Thromb Res2017; 157: 46–48.
21.
SøgaardMNielsenPBSkjøthF, et al.Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism. Am J Med2018; 131: 787–794.e4.
22.
UtneKKDahmAWikHS, et al.Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. Thromb Res2018; 163: 6–11.
23.
ColemanCIBeyer-WestendorfJBunzTJ, et al.Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism. Clin Appl Thromb Hemost2018; 24: 575–582.
24.
De Athayde SoaresRMatieloMFBrochado NetoFC, et al.Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. Surgery2019; 166: 1076–1083.
25.
FerreiraTHuberSCde Moraes MartinelliB, et al.Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban. Vasc Pharmacol2020; 124: 106608.
26.
PrandoniPAgenoWCiammaichellaM, et al.The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants. Intern Emerg Med2020; 15: 447–452.
27.
WikHSKahnSRErikssonH, et al.Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: a long-term cross-sectional follow-up of RE-COVER study patients. J Thromb Haemostasis2021; 19: 2495–2503.
28.
PrandoniPAgenoWMumoliN, et al.Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants. Thromb Res2017; 153: 97–100.
29.
AgnelliGGallusAGoldhaberSZ, et al.Treatment of proximal deep-vein thrombosis with the oral direct factor xa inhibitor rivaroxaban (BAY 59-7939). Circulation2007; 116: 180–187.
30.
TerryCMHeYCheungAK, et al.Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res2016; 144: 106–112.
31.
RabinovichACohenJMCushmanM, et al.Inflammation markers and their trajectories after deep vein thrombosis in relation to the risk of post-thrombotic syndrome. J Thromb Haemostasis2015; 13: 398–408.
32.
HullRDLiangJTownshendG. Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review. Am J Med2011; 124: 756–765.
33.
GalanaudJPHolcroftCARodgerMA, et al.Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency. J Thromb Haemostasis2013; 11: 474–480.
34.
FerreiraAMOliveira-PintoJDuarte-GamasL, et al.Mid-term patency of iliac venous stenting for post-thrombotic syndrome. Int Angiol2021; 40: 196–205.
35.
HaigYEndenTGrøttaO, et al.Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol2016; 3: e64–e71.
